

## Notice under section 708A(5)(e) of the *Corporations Act 2001* (Cth)

This notice is given by INOVIQ Limited ACN 009 070 384 (ASX:IIQ) (**Company**) under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Corporations Act**).

The Company today issued 27,142,856 fully paid ordinary shares (**Shares**) at an issue price of A\$0.35 per Share using the Company's existing placement capacity under listing rules 7.1 and 7.1A.

The Company advises that:

- (a) the Shares the subject of this notice were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
- (b) this notice is being given under section 708A(5)(e) of the Corporations Act;
- (c) as at the date of this notice, the Company has complied with:
  - (i) the provisions of Chapter 2M of the Corporations Act, as they apply to the Company; and
  - (ii) sections 674 and 674A of the Corporations Act; and
- (d) as at the date of this notice, there is no "excluded information" within the meanings of sections 708A(7) and 708A(8) of the Corporations Act.

This document is authorised for release by the directors of INOVIQ Limited.

### FURTHER INFORMATION

**Dr Leearne Hinch**  
Chief Executive Officer  
E [lhinch@inoviq.com](mailto:lhinch@inoviq.com)  
M +61 400 414 416

**David Williams**  
Chairman  
E [dwilliams@kidder.com.au](mailto:dwilliams@kidder.com.au)  
M +61 414 383 593

### ABOUT INOVIQ LTD

INOVIQ Ltd (ASX: IIQ) is a leader in exosome technology advancing next-generation diagnostics and therapeutics that transform cancer care. Our product portfolio includes commercial-stage exosome isolation products, clinical-stage diagnostics for ovarian and breast cancers, and a cutting-edge preclinical CAR-exosome therapeutic program for solid tumours. INOVIQ is shaping the future of cancer detection and treatment to improve patient outcomes. For more information on INOVIQ, visit [www.inoviq.com](http://www.inoviq.com).